selected scholarly activity
-
conferences
- A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI). Annals of Oncology. vi167-vi167. 2016
- Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.. Journal of Clinical Oncology. 5547-5547. 2016
- Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia.. Journal of Clinical Oncology. 5586-5586. 2016
- A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.. Journal of Clinical Oncology. 3061-3061. 2015
- NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. Journal of Clinical Oncology. 2594-2594. 2015
- Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial.. Journal of Clinical Oncology. 2000-2000. 2015
- A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.. Journal of Clinical Oncology. TPS5631-TPS5631. 2014
- A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.. Journal of Clinical Oncology. 5519-5519. 2014
- Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.. Journal of Clinical Oncology. 2535-2535. 2014
- Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.. Journal of Clinical Oncology. TPS5629-TPS5629. 2014
- Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium.. Journal of Clinical Oncology. TPS5620-TPS5620. 2014
- A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies. Journal of Clinical Oncology. 2013
- A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.. Journal of Clinical Oncology. 2013
- Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors.. Journal of Clinical Oncology. 2013
- Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr plus T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041). Journal of Clinical Oncology. 2013
- Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program. Journal of Clinical Oncology. 2013
- A PHASE I STUDY OF THE COMBINATION OF RO4929097 (RO) AND CEDIRANIB (CD) IN PATIENTS WITH ADVANCED SOLID TUMORS (PJC-004/NCI 8503). Annals of Oncology. 155-156. 2012
- A PHASE IB COMBINATION STUDY OF RO4929097 (RO), A GAMMA-SECRETASE INHIBITOR, AND TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS. Annals of Oncology. 156-156. 2012
- A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Journal of Clinical Oncology. 2012
- A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in advanced platinum (Pt)-resistant (R) ovarian cancer (OC): A study of the PMH, Chicago, and California phase II consortia. Journal of Clinical Oncology. 2012
- Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. Journal of Clinical Oncology. 2012
- Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial.. Journal of Clinical Oncology. 2012
- A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.. Journal of Clinical Oncology. 3099-3099. 2011
- The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5.. Journal of Clinical Oncology. 5088-5088. 2011
- 491 NCIC CTG IND.177: Phase I study of AT7519M given as a short infusion twice weekly. European Journal of Cancer, Supplement. 157-157. 2010
- A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia. Journal of Clinical Oncology. 2010
- Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.. Journal of Clinical Oncology. 3002-3002. 2010
- Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.. Journal of Clinical Oncology. 5002-5002. 2010
- Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.. Journal of Clinical Oncology. 3077-3077. 2010
- Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors. Molecular Cancer Therapeutics. A185-A185. 2009
- Abstract B54: A phase 1 study to assess the safety, tolerability and pharmacokinetics of the ErbB-family inhibitor ARRY-334543 in patients with advanced solid tumors. Molecular Cancer Therapeutics. B54-B54. 2009
- A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer. Journal of Clinical Oncology. 2009
- A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. Journal of Clinical Oncology. 2009
- OGX-427, a 2 ' methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial. Journal of Clinical Oncology. 2009
- 112 POSTER A clinical chemistry approach for identifying biomarkers as surrogate endpoints in therapy directed against chemokine mediated metastasis. European Journal of Cancer, Supplement. 37-37. 2008
- 206 POSTER Phase II study of sunitinib in patients (pts) with progressive metastatic adenoid cystic carcinoma (ACC). European Journal of Cancer, Supplement. 65-65. 2008
- 405 POSTER Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. European Journal of Cancer, Supplement. 127-127. 2008
- A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. Journal of Clinical Oncology. 5521-5521. 2008
- A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. Journal of Clinical Oncology. 5582-5582. 2008
- A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial. Journal of Clinical Oncology. 5518-5518. 2008
- A phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms. Molecular Cancer Therapeutics. 3371S-3371S. 2007
- Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers. Molecular Cancer Therapeutics. 3385S-3386S. 2007
- Dose banding of chemotherapy doses at the Juravinski Cancer Centre.. Journal of Clinical Oncology. 325S-325S. 2006
- HGS-ETR1, a fully human agonistic monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.. Clinical Cancer Research. 9104S-9104S. 2005
- A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial. Journal of Clinical Oncology. 223S-223S. 2005
- HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial.. Journal of Clinical Oncology. 204S-204S. 2005
- Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Journal of Clinical Oncology. 171S-171S. 2004
- Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study. Journal of Clinical Oncology. 204S-204S. 2004
- Phase II study of topotecan (T) in combination with the novel kinase inhibitor ucUCN-01 in patients with advanced cancer.. Clinical Cancer Research. 6223S-6223S. 2003
- TRANSIENT GLOBAL AMNESIA FOLLOWING INTRAVENOUS HEPARIN BOLUS THERAPY IS CAUSED BY HEPARIN-INDUCED THROMBOCYTOPENIA. Thrombosis and Haemostasis. 911-911. 1993
-
journal articles
- Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Critical Reviews in Oncology/Hematology. 162:103336-103336. 2021
- A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecologic Oncology. 137:216-222. 2015
- A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Investigational New Drugs. 32:1226-1235. 2014
- A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Investigational New Drugs. 32:243-249. 2014
- A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). British Journal of Cancer. 109:943-949. 2013
- Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. International Journal of Cancer. 132:1547-1555. 2013
- Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. OncoTargets and Therapy. 6:427-427. 2013
- Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas. Clinical Cancer Research. 17:1582-1590. 2011
- Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. British Journal of Cancer. 104:756-762. 2011
- Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium. International Journal of Gynecological Cancer. 20:787-793. 2010
- Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study. Journal of Clinical Oncology. 27:3097-3103. 2009
- Novel developments in angiogenesis cancer therapy. Current Oncology. 16:191-195. 2009
- Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL). Clinical Cancer Research. 27:3528-3528. 2009
- Novel Developments in Angiogenesis Cancer Therapy. Current Oncology. 16:50-54. 2009
- Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones. Journal of Clinical Oncology. 26:3301-3302. 2008
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 14:3450-3455. 2008
- Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents. Journal of Clinical Oncology. 26:1324-1330. 2008
- Optimal Chemotherapy Treatment for Women with Recurrent Ovarian Cancer. Current Oncology. 14:195-208. 2007
- UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium. Gynecologic Oncology. 106:305-310. 2007
- Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors. Oncologist. 12:426-437. 2007
- Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancer. Cancer. 109:692-702. 2007
- An Optimized Clinical Regimen for the Oncolytic Virus PV701. Clinical Cancer Research. 13:977-985. 2007
- Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. International Journal of Gynecological Cancer. 17:1194-1204. 2007
- Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination. Clinical Cancer Research. 12:2141-2149. 2006
- Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Annals of Oncology. 17:334-340. 2006
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Annals of Oncology. 16:1688-1694. 2005
- A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Investigational New Drugs. 23:165-170. 2005
- A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers. Annals of Oncology. 15:665-670. 2004
- A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.. Clinical Cancer Research. 9:2457-2464. 2003
- BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies. Current Pharmaceutical Design. 8:2249-2253. 2002
- Malignant Ascites Fluid (MAF), Including Ovarian-Cancer-Associated MAF, Contains Angiostatin and Other Factor(s) Which Inhibit Angiogenesis. Gynecologic Oncology. 86:279-287. 2002
- Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer.. Cancer Research. 62:1588-1591. 2002
- Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum--a systematic review of the evidence from randomized trials.. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. 23:104-110. 2002
- Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study. International Journal of Cancer. 91:857-862. 2001
- Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure. International Journal of Gynecological Cancer. 10:463-468. 2000
- Induction of hTERT Expression and Telomerase Activity by Estrogens in Human Ovary Epithelium Cells. Molecular and Cellular Biology. 20:3764-3771. 2000
- Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells.. Clinical and Experimental Metastasis. 17:33-42. 1999
- A Randomized Trial of Paracentesis plus Intraperitoneal Tumor Necrosis Factor-α versus Paracentesis Alone in Patients with Symptomatic Ascites from Recurrent Ovarian Carcinoma. Gynecologic Oncology. 64:80-87. 1997
- Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.. Invasion and Metastasis. 17:312-322. 1997
- Telomerase activity associated with acquisition of malignancy in human colorectal cancer.. Cancer Research. 55:2533-2536. 1995
- Transient global amnesia associated with acute heparin-induced thrombocytopenia. American Journal of Medicine. 97:489-491. 1994
- Establishment and characterization of four human epithelial ovarian carcinoma cell lines. Cancer. 74:900-906. 1994
- Telomerase activity in human ovarian carcinoma.. Proceedings of the National Academy of Sciences of the United States of America. 91:2900-2904. 1994
- Telomerase, Cell Immortality, and Cancer. Cold Spring Harbor Symposia on Quantitative Biology. 59:307-315. 1994
- Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-β in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cellular Immunology. 142:207-216. 1992
- A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma. Gynecologic Oncology. 44:223-226. 1992
- Factors determining the ability of cytokine-activated killer cells to lyse human ovarian carcinoma targets. Cellular Immunology. 136:122-132. 1991
- Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumour. British Journal of Cancer. 58:415-418. 1988